Restart Life Sciences Corp.
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. … Read more
Restart Life Sciences Corp. (NMLSD) - Total Liabilities
Latest total liabilities as of June 2025: $214.89K USD
Based on the latest financial reports, Restart Life Sciences Corp. (NMLSD) has total liabilities worth $214.89K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Restart Life Sciences Corp. - Total Liabilities Trend (2020–2024)
This chart illustrates how Restart Life Sciences Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Restart Life Sciences Corp. Competitors by Total Liabilities
The table below lists competitors of Restart Life Sciences Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liminatus Pharma, Inc. Warrants
NASDAQ:LIMNW
|
USA | $2.99 Million |
|
Next10 Inc
PINK:NXTN
|
USA | $6.64 Million |
|
World Chess PLC
LSE:CHSS
|
UK | GBX2.97 Million |
|
Thunderbird Minerals Corp.
V:BIRD
|
Canada | CA$217.97K |
|
Neovacs S.A.
PA:ALNEV
|
France | €4.18 Million |
|
Reem Capital Corp.
V:REEM-P
|
Canada | CA$82.37K |
|
Theracryf Plc
LSE:TCF
|
UK | GBX1.82 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Restart Life Sciences Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Restart Life Sciences Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Restart Life Sciences Corp. (2020–2024)
The table below shows the annual total liabilities of Restart Life Sciences Corp. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $489.47K | -41.85% |
| 2023-12-31 | $841.66K | +229.49% |
| 2022-12-31 | $255.44K | -39.48% |
| 2021-12-31 | $422.06K | +10.21% |
| 2020-12-31 | $382.96K | -- |